Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RadNetFRA:PQIA +0.72%79 3-Year RORE % is 159.71 as of Mar. 2026. GuruFocus rates FRA:PQIA with a GF Score™ of 79/100 and a GF Value™ of €59.08 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, RadNet ranks better than 96.5% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
RadNet's 3-Year RORE % for the quarter that ended in Mar. 2026 was 159.71%.
The industry rank for RadNet's 3-Year RORE % or its related term are showing as below:
FRA:PQIA's 3-Year RORE % is ranked better than 96.5% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: -7.935
vs FRA:PQIA: 159.71
RadNet (FRA:PQIA) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
RadNet 3-Year RORE % Related Terms
RadNet 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for RadNet's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PQIA vs VCYT, SHC, BLLN: 3-Year RORE % Comparison
For the Diagnostics & Research subindustry, RadNet's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RadNet 3-Year RORE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, RadNet's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where RadNet's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
RadNet (FRA:PQIA) has a 3-Year RORE % of 159.71 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on RadNet and its competitors. According to the industry distribution chart, RadNet ranks #7 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 3.5%.
Is RadNet's 3-Year RORE % too high?
RadNet's current 3-Year RORE % is 159.71. Based on the distribution chart, RadNet ranks #7 out of 200 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, RadNet has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RadNet's 3-Year RORE % compare to VCYT and SHC?
According to the Medical Diagnostics & Research industry distribution chart, RadNet ranks #7 out of 200 companies for 3-Year RORE %. This places RadNet in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Diagnostics & Research company?
A good 3-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on RadNet and its competitors. RadNet's current 3-Year RORE % is 159.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RadNet stock overvalued right now?
Based on GuruFocus' analysis, RadNet (FRA:PQIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €59.08, compared to a current price of €53.38 — trading 9.6% below its estimated fair value. The current 3-Year RORE % is 159.71. RadNet's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For RadNet (FRA:PQIA), the current 3-Year RORE % is 159.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RadNet (FRA:PQIA) Overvalued in 2026?
Based on GuruFocus' analysis, RadNet stock appears to be undervalued.
The current stock price of €53.38 is trading 9.6% below its estimated GF Value™ of €59.08.
GuruFocus considers RadNet to be Modestly Undervalued.
Key valuation signals for FRA:PQIA:
3-Year RORE %: 159.71
GF Value™: €59.08 vs. price of €53.38 (9.6% below fair value)
No single metric tells the full story. See the FRA:PQIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostic.
79GF Score
Get the complete analysis for FRA:PQIA
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PQIA has been successfully added to your 
